Study of Volrustomig for High-Risk Locally Advanced Cervical Cancer
This study is looking at a treatment called volrustomig for women with high-risk locally advanced cervical cancer (cancer that has spread to nearby tissues but not distant parts of the body). Participants will receive either volrustomig or a placebo (an inactive substance) through an IV. Researchers want to see if volrustomig can help prevent the cancer from growing or spreading (progression-free survival). You may be able to join if you are a woman aged 15 or older, weigh over 35 kg, and have not had your cancer worsen after platinum-based chemotherapy and radiation. The study aims to enroll 800 participants, but its current recruitment status is unclear.
- Study design
- This is a large study where 800 participants will be randomly assigned to receive either volrustomig or a placebo, and neither you nor your doctors will know which you are receiving.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be followed for up to approximately 7 years to track how long you live without your cancer progressing.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
At a glance
Conditions
Where it's being run
205 sites across 34 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Progression-free Survival (PFS) based on the investigator assessment in all randomized participants (FAS)Up to approximately 7 years
PFS is defined as the time from date of randomization until RECIST 1.1- defined radiological progression or histopathologically confirmed progression as assessed by the Investigator or death due to any cause, whichever occurs earlier.